• Explore /
  • Poster
  • / Trastuzumab (T) plus gemcitabine-cisplatin (GC) for treatment naïve HER2 positive biliary tract adenocarcinomas (BTC): A multicentre open-label, phase II study (TAB).

Trastuzumab (T) plus gemcitabine-cisplatin (GC) for treatment naïve HER2 positive biliary tract adenocarcinomas (BTC): A multicentre open-label, phase II study (TAB).

Abstract Poster

Authors

null

Vikas S. Ostwal

Tata Memorial Hospital (HBNI), Mumbai, India

Vikas S. Ostwal , Sarika Mandavkar , Prabhat Ghanshyam Bhargava , Sujay Srinivas , Chaitali Nashikkar , Omshree Shetty , Rajiv Kumar Kaushal , Subhash Yadav , Aekta Shah , Akshay Dwarka Baheti , Suman Kumar Ankathi , Daksha Mehta , Akhil Kapoor , Mahesh Goel , Shraddha Patkar , Deepali Chaugule , Anant Ramaswamy

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer - Advanced/Metastatic Disease

Clinical Trial Registration Number

CTRI/2019/11/021955

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 4089)

DOI

10.1200/JCO.2023.41.16_suppl.4089

Abstract #

4089

Poster Bd #

410

Abstract Disclosures

Similar Posters

First Author: Zhi Peng

First Author: Kohei Shitara

First Author: Yelena Y. Janjigian

Poster

2024 ASCO Gastrointestinal Cancers Symposium

Characterizing outcomes of ERBB2-amplified biliary tract cancer.

Characterizing outcomes of ERBB2-amplified biliary tract cancer.

First Author: Daniel Aaron Fox